• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.

作者信息

Quercia Romina, Amiel Corinne, Marechal Elisete Da Silva, Lebrette Marie-Gisèle, Thevenet Sandrine, Renaud Stéphanie, Schneider Véronique, Kara Ali, Guessant Sabine, Pialoux Gilles

出版信息

J Acquir Immune Defic Syndr. 2006 Jul;42(3):389-90. doi: 10.1097/01.qai.0000225018.35643.d9.

DOI:10.1097/01.qai.0000225018.35643.d9
PMID:16763531
Abstract
摘要

相似文献

1
Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.替诺福韦/去羟肌苷/拉米夫定方案的病毒学和免疫学疗效。
J Acquir Immune Defic Syndr. 2006 Jul;42(3):389-90. doi: 10.1097/01.qai.0000225018.35643.d9.
2
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.在随机评估替拉那韦对多重耐药患者的策略性干预（RESIST）研究中，接受替拉那韦/利托那韦与替诺福韦和去羟肌苷联合给药的患者免疫恢复受损。
J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):479-81. doi: 10.1097/QAI.0b013e318061b76e.
3
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Checking up on ddI and tenofovir in people with HIV/AIDS.
TreatmentUpdate. 2003 Apr-May;15(3):4-5.
4
Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨对比：ACTG 5202的中期结果
AIDS Clin Care. 2008 Apr;20(4):28.
5
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.在初治的1型人类免疫缺陷病毒感染患者中，使用阿德福韦酯、拉米夫定、去羟肌苷和依非韦伦进行每日一次的四联药物治疗。
J Infect Dis. 2002 Oct 1;186(7):1028-33. doi: 10.1086/343740. Epub 2002 Sep 13.
6
Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.对于因去羟肌苷导致毒性的患者，从去羟肌苷/拉米夫定转换为替诺福韦/恩曲他滨后，空腹血脂和肝毒性迅速改善。
HIV Clin Trials. 2010 Mar-Apr;11(2):118-20. doi: 10.1310/hct1102-118.
7
High rate of virologic failure with once-daily ddI/3TC/TDF.
IAPAC Mon. 2003 Nov;9(11):279.
8
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.齐多夫定、拉米夫定和替诺福韦治疗失败后HIV-1的克隆耐药性分析
Antivir Ther. 2010;15(3):437-41. doi: 10.3851/IMP1539.
9
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.在接受替诺福韦加去羟肌苷作为核苷类逆转录酶抑制剂骨干治疗的有治疗经验的成年人中，T细胞和自然杀伤细胞功能的保守性。
Clin Exp Immunol. 2009 Oct;158(1):55-63. doi: 10.1111/j.1365-2249.2009.03988.x.
10
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.两种新型抗逆转录病毒核苷类似物固定剂量配方的近期可得性：一项针对初治和经治患者对其实际应用及治疗前景的为期12个月的前瞻性开放标签调查。
AIDS Patient Care STDS. 2008 Apr;22(4):279-90. doi: 10.1089/apc.2007.0141.